Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September,2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx Ltd (formerly Kilpest India Ltd) reported steady results for Q2 and H1 FY26. Standalone revenue from operations grew to ₹2,791.16 lakhs in Q2 (vs ₹2,657.49 lakhs in Q2 FY25) and ₹4,826.87 lakhs for H1 (vs ₹4,407.88 lakhs). Standalone profit after tax rose to ₹1,494.08 lakhs for Q2 and ₹2,740.12 lakhs for H1, with basic EPS of ₹31.98 for the half year. On a consolidated basis, H1 revenue from operations reached ₹5,673.67 lakhs (vs ₹4,858.10 lakhs) and profit after tax stood at ₹2,768.21 lakhs, with EPS of ₹32.37. The company completed the acquisition of Coris Holding SRL (Belgium) on 29 August 2025, and incurred one-time M&A advisory and due diligence costs of ₹138.46 lakhs in H1. The statutory auditor (M/s Baheti & Co.) issued a clean limited review report with no qualifications.
Results show modest topline growth and stable margins, partly boosted by the consolidation of newly acquired Coris Holding SRL from late August. The acquisition expands the company's diagnostic kits footprint in Europe, though the one-time M&A expenses slightly weighed on other expenses. Overall, the numbers are constructive for shareholders with no negative audit observations.